The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
-
TRENDS 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
-
REGULATORY MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
-
REGULATORY Japan Approves Roche/Chugai’s Tumor-Agnostic Rozlytrek, Alnylam’s RNAi Drug and More
June 19, 2019
-
TRENDS Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
June 18, 2019
-
ORGANIZATION Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
-
BUSINESS Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
June 14, 2019
-
REGULATORY Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
-
BUSINESS Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
-
BUSINESS Japan Ethical Drug Sales Shrivel, but Many Beat Conservative Guidance
June 11, 2019
-
REGULATORY MHLW Study Group Drafting Guidelines for New Dyslipidemia Drug Development, First in 30 Years
June 11, 2019
-
BUSINESS Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
-
BUSINESS Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
-
ORGANIZATION Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
-
ORGANIZATION Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
-
REGULATORY Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
-
BUSINESS Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
-
REGULATORY June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug
May 31, 2019
-
REGULATORY LDP Junior Politicians Set Up Vaccine Study Group
May 31, 2019
-
BUSINESS Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…